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Abstract
We present a generic, multidisciplinary approach for improving our understanding of novel missense variants in recently
discovered disease genes exhibiting genetic heterogeneity, by combining clinical and population genetics with protein
structural analysis. Using six new de novomissense diagnoses in TBL1XR1 from theDeciphering Developmental Disorders study,
together with population variation data, we show that the β-propeller structure of the ubiquitous WD40 domain provides a
convincing way to discriminate between pathogenic and benign variation. Children with likely pathogenic mutations in this
gene have severely delayed language development, often accompanied by intellectual disability, autism, dysmorphology and
gastrointestinal problems. Amino acids affected by likely pathogenic missense mutations are either crucial for the stability
of the fold, forming part of a highly conserved symmetrically repeating hydrogen-bonded tetrad, or located at the top face of the
β-propeller, where ‘hotspot’ residues affect the binding of β-catenin to the TBLR1 protein. In contrast, those altered by
population variation are signiﬁcantly less likely to be spatially clustered towards the top face or to be at buried or highly
conserved residues. This result is useful not only for interpreting benign andpathogenicmissense variants in this gene, but also
in other WD40 domains, many of which are associated with disease.
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Introduction
Understanding the impact of missense variants in known dis-
ease genes is a major challenge for the clinical application of
genomics (1,2). A handful of well-known disease genes [such
as CFTR (3) and TP53 (4)] have been extremely well studied over
several decades through both research and clinical genetic test-
ing, and multiple known pathogenic missense variants have
been individually characterized in silico, in vitro and in vivo.
However, the rate of gene discovery has grown exponentially
since the completion of the human genome sequence (5): nearly
3500 suspected disease genes are currently listed inOMIM,many
of which have been discovered through exome sequencing
of patients with rare diseases (6) with rare nonsense or pro-
tein-truncatingmutations. Many such genes are, as yet, unstud-
ied and very sparsely populated with known pathogenic (or
benign)missense variants, somost raremissense variants iden-
tiﬁed in these genes are likely to be novel. Meanwhile, massively
parallel sequencing technologies are increasingly being used for
clinical genetic testing in the form of multigene panels, exome
sequencing and even whole-genome sequencing (7). As a result,
a plethora of previously uncharacterized missense variants are
being discovered regularly in known disease genes (8–10),
where the consequence for protein structure, cellular processes
or disease aetiology is unclear, severely compromising their
clinical utility.
The increasing availability of exome sequencing and whole-
genome sequencing in research means that the pervasiveness
of normal genetic variation is starting to become clear. A nor-
mal human genome contains three to four million variants, of
which approximately 10 000 will be non-synonymous variants
in coding exons predicted to cause a missense change, altering
a single amino acid in the resulting protein (11,12). However,
despite the fact that missense variation is extraordinarily
commonplace, most genes still do not yet contain sufﬁcient
conﬁrmed pathogenic and benign missense variants upon
which to build detailed speciﬁc models to understand and ac-
curately predict their relationship to human disease. Although
numerous increasingly useful pathogenicity predictors exist
(13–18), they generally have low speciﬁcity (9,19) and are based
on sequence alignments that often exclude detailed knowledge
of three-dimensional (3D) protein structure. However, as the
same structural domain is commonly present in different
proteins, encoded by different genes, and associated with dif-
ferent diseases, amethod heavily informed by protein structure
analysis is likely to yield insights across multiple genes and
diseases.
Sequence data on normal population variation coupled
with high throughput exome/genome sequencing of patients
with rare diseases offer the perfect opportunity to investigate
whether there are systematic differences between pathogenic
and benign missense variants at an individual gene or protein
level. Here, we use novel diagnostic de novomutations identiﬁed
through the Deciphering Developmental Disorders (DDD) study
(20,21) as an example to explore the application of detailed
protein structure analysis to the understanding of disease. As a
proof of principle, we focus here on the WD40 domain, one of
the most abundant structural domains in eukaryotic genomes
(22). Different WD40-containing genes have already been
associated with multiple diseases (23,24), including TBL1XR1
[transducin (beta)-like 1 X-linked receptor 1], in which haploin-
sufﬁciency has recently been linked to autism spectrum
disorders (25,26) and developmental delay (27–29) (OMIM no.
608628). The encoded TBL1-related protein 1 (UniProt ID
Q9BZK7) is involved in a transcription signalling pathway and
comprises two structural domains: an LisH domain (30) and a
WD40 β-propeller domain (31). Here, we use this gene to investi-
gate the value of integrating population variation and protein
structural analysis to improve clinical interpretation ofmissense
variation.
Results
Six children within the DDD study were found to have likely
pathogenic de novo mutations in TBL1XR1, including ﬁve single
nucleotide variants predicted to cause a missense change, and
one 1 bp frameshift insertion predicted to result in loss of func-
tion through truncation or nonsense-mediated decay (Table 1).
Two additional likely de novo missense mutations have also
been published in children affected by developmental disor-
ders (25,28), as well as a de novo 1 bp frameshift deletion (25).
A number of whole gene deletions have also been described
(27,29).
Children with likely pathogenic mutations in TBL1XR1 have
developmental delay oftenwith autistic features (Table 1). All pa-
tients have marked expressive speech and language delay as the
most consistent feature, and most have special needs requiring
specialist educational assistance. In addition, most of the chil-
dren identiﬁed via the DDD study have gastrointestinal disturb-
ance or constipation. Although a number of patients have
dysmorphic features, a preliminary assessment of facial photo-
graphs does not suggest an identiﬁable facial gestalt and growth
parameters were typically within the normal range (Supplemen-
tary Material, Table S1). There are no apparent differences in ei-
ther the phenotypes or severity of the children with missense
mutations versus those with truncating mutations and gene de-
letions, potentially suggesting a common loss of function
mechanism.
Although TBL1XR1 is a highly constrained gene [ExomeAggre-
gation Consortium (ExAC), Cambridge, MA, USA; http://exac.
broadinstitute.org/; accessed December 2015], we were able to
identify 64 unique germline population missense variants in
TBL1XR1 in population controls, in which benign variants are ex-
pected to be relatively enriched and pathogenic variants relative-
ly depleted for rare childhood onset dominant disorders with
obvious phenotypes. These variants were identiﬁed using mul-
tiple databases: the ExAC (http://exac.broadinstitute.org/; ac-
cessed June 2015), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/),
the Exome Variant Server [NHLBI GO Exome Sequencing Project
(ESP), Seattle, WA, USA; http://evs.gs.washington.edu/EVS/; ac-
cessed June 2015] and the European Variant Archive (http://
www.ebi.ac.uk/eva/) (32).
All ﬁve DDD missense mutations and one published likely
pathogenic mutation are located within the WD40 domain of
TBLR1, in addition to 33 of the population missense variants
(Table 2). Interestingly,we also identiﬁed 16 likely non-pathogen-
ic missense variants in TBL1XR1 within the DDD cohort (where
the variant is in, or inherited from, an unaffected parent), all of
which either lie outside the WD40 domain or have already been
observed in the population.
The WD40 domain of TBLR1 has a β-propeller structure con-
sisting of eight propeller ‘blades’, each formed by a four-stranded
antiparallel β-sheet, which are joined by β-hairpins. The blades
are arranged symmetrically about a central axis, like the staves
of a barrel, and β-catenin binds to the ‘top’ face of the propeller
to promote the transcription of Wnt target genes (33) (Fig. 1B).
A number of ‘hotspot residues’ have been identiﬁed previously
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Table 1. Summary of the clinical features in children with diagnostic variants in TBL1XR1
Reference Patient ID Age (years) Sex Mutation HGVS Clinical features First words
DDDa DECIPHER259340 11 M De novo missense ENST00000430069.1c.1322A > G
ENSP00000405574.1:p.(His441Arg)
Global developmental delay 3 years
DDDa DECIPHER261213 14 F De novo missense ENST00000430069.1:c.1108G > T
ENSP00000405574.1:p.(Asp370Tyr)
Global developmental delay Non-verbal
DDDa DECIPHER271955 5 M De novo missense ENST00000430069.1:c.983A > G
ENSP00000405574.1:p.(Asp328Gly)
Global developmental delay Non-verbal
DDDa DECIPHER273334 6 F De novo missense ENST00000430069.1:c.1331C >G
ENSP00000405574.1:p.(Pro444Arg)
Global developmental delay, autism 2 years
DDDa DECIPHER280701 7 M De novo missense ENST00000430069.1:c.639T > A
ENSP00000405574.1:p.(His213Gln)
Global developmental delay, autism 1 year
DDDa DECIPHER260965 5 M De novo frameshift ENST00000430069.1:c.800dupG
ENSP00000405574.1:p.
(Ile269TyrfsTer8)
Global developmental delay, autism 2–2.5 years
Saitsu et al. (28) ClinVar 191371 5 F De novo missense ENST00000430069.1:c.209G >A
ENSP00000405574.1p.(Gly70Asp)
Developmental delay, autistic features Non-verbal
O’Roak et al. (25) NA Not known F De novo missense ENST00000430069.1:c.845T > C
ENSP00000405574.1:p.(Leu282Pro)
Mild/moderate IQ, autism Unknown
O’Roak et al. (25) NA Not known M De novo frameshift ENST00000430069.1:c.1190delT
ENSP00000405574.1:p.
(Ile397SerfsTer19)
Autism Unknown
Pons et al. (27) NA 8 F Maternally inherited gene
deletion
707 kb deletion
(chr3:176 221 801–176 929 584)
Intellectual disability, dysmorphism (also observed
in mother)
Delayed
Tabet et al. (29) NA 6 F De novo gene deletion 1.6 Mb deletion
(chr3:175 507 453–177 095 072)
Intellectual disability, dysmorphism 2.5 years
See Supplementary Material, Table S1 for a more detailed clinical description. Variants are an notated using standard HGVS nomenclature (for simplicity, parentheses indicatingmissense prediction are omitted throughout the text).
aVariants deposited in DECIPHER database (https://decipher.sanger.ac.uk).
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(31) on the top face of the domain (34), which are likely to be in-
volved in the protein’s interaction with β-catenin. In addition,
the amino acid sequence of each blade of the β-propeller in
most WD40 domains, including that in TBLR1, exhibits a recog-
nizable pattern of residues known as the WD40 repeat motif,
with certain residue types favoured in speciﬁc positions. The
PROSITE sequence logo (35) for this motif is shown in Figure 2A,
inwhich taller letters identify the highly conserved residues that
are important for stabilization of the blade’s structure. The
TBLR1 protein has six complete tetrads and one incomplete tet-
rad that ismissing the tryptophan residue (Fig. 2B). Of note in the
logo are the histidine, serine/threonine, aspartic acid and trypto-
phan residues at motif positions 4, 22, 26 and 32, respectively.
These form the Asp-His-Ser/Thr-Trp (DHSW) tetrad—a network
of ‘unusually strong’ hydrogen bonds that maintains the do-
main’s thermostability (37) (Fig. 3). The aspartic acid at motif
position 26 is present in all eight blades and plays an especially
important role in stabilizing the beta-hairpin structure at the top
of each blade via two hydrogen bonds to themain chain nitrogen
atoms of adjoining strands. An experimental study in 2010
showed that, although mutations to the tetrad residues main-
tained the domain’s 3D structure, as evidenced by crystal struc-
tures of the mutant proteins, the stability of the proteins was
severely affected (37), potentially interfering with folding or
function.
Table 2. All missense variants identiﬁed in TBL1XR1 overlapping the
WD40 domain of TBLR1 (June 2015; see also Fig. 4)
Variation Source
(allele
count)
Location
(GRCh37)
Ref/
alt
Predicted
amino acid
change
Population ExAC (1) chr3:176768368 C/T Gly153Glu
Population dbSNP chr3:176768338 A/G Val163Ala
Population ExAC (1) chr3:176768288 C/T Val180Ile
Population ExAC (1) chr3:176767892 T/A Ser199Cys
Population ExAC (1) chr3:176767879 G/C Thr203Ser
Diagnostic DDD chr3:176767848 A/T His213Gln
Population ExAC (1) chr3:176765173 C/T Ser260Asn
Population dbSNP chr3:176765158 T/C His265Arg
Diagnostic O’Roak
et al. (25)
chr3:176765107 A/G Leu282Pro
Population ExAC (1) chr3:176756189 T/C Asn320Ser
Population dbSNP chr3:176756189 T/G Asn320Thr
Population EVA chr3:176756187 T/C Thr321Ala
Diagnostic DDD chr3:176756165 T/C Asp328Gly
Population ExAC (1) chr3:176756102 G/T Thr349Lys
Population ExAC (2) chr3:176755930 T/C Thr360Ala
Population dnSNP chr3:176755930 T/A Thr360Ser
Population ExAC (1) chr3:176755923 T/G Asn362Thr
Diagnostic DDD chr3:176755900 C/A Asp370Tyr
Population ExAC (1) chr3:176752065 T/C Asn391Asp
Population ExAC (2) chr3:176752022 C/T Gly405Glu
Population ExAC (5) chr3:176752016 T/C Asn407Ser
Population dbSNP chr3:176752017 T/C Asn407Asp
Population ExAC (1) chr3:176752014 T/C Asn408Asp
Population ExAC (1) chr3:176750916 A/C Phe420Cys
Population ExAC (1) chr3:176750908 T/C Thr423Ala
Population ExAC (1) chr3:176750905 C/G Val424Leu
Population ExAC (1) chr3:176750884 G/C Arg431Gly
Population dbSNP chr3:176750883 C/T Arg431Gln
Population dbSNP chr3:176750860 T/C Thr439Ala
Population dbSNP chr3:176750855 T/G Lys440Asn
Diagnostic DDD chr3:176750853 T/C His441Arg
Diagnostic DDD chr3:176750844 G/C Pro444Arg
Population ExAC (1) chr3:176750817 T/C Asp453Gly
Population ExAC (2) chr3:176750811 C/T Arg455Lys
Population ExAC (27) chr3:176744255 G/A Ala475Val
Population ExAC (1) chr3:176744247 G/C His478Asp
Population ExAC (1) chr3:176744189 T/C Lys497Arg
Population dbSNP chr3:176743294 G/A Arg513Trp
Population ExAC (1) chr3:176743291 T/G Lys514Gln
Figure 1. Structure of TBLR1. (A) Domain structure with location of diagnostic
missense mutations. The ﬁve new DDD mutations are indicated in black and
the two previously published mutations in grey. (B) Three-dimensional β-
propeller structure of the WD40 domain from PDB entry 4lg9, top and side
views. The eight propeller blades are rainbow coloured, starting with red for the
N-terminus through to violet for the C-terminus.
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The ﬁve DDDmissense mutations are His213Gln, Asp328Gly,
Asp370Tyr, His441Arg and Pro444Arg. The ﬁrst four involve his-
tidine and aspartic acid residues from different symmetrically
repeated DHSW tetrads, at positions 4 and 26 in the WD40
motif (Fig. 2B), so that their change is likely to disrupt the stabil-
ity of the protein’s fold. Of particular interest is the highly con-
served aspartic acid at position 26 in the WD40 motif, which
can hydrogen-bond to the tetrad’s histidine and also to a
main-chain nitrogen on the preceding propeller blade (Thr349
in Fig. 3), and to a main-chain nitrogen two residues down
(Thr372 in Fig. 3). In their native state, both are structurally sta-
bilizing interactions, helping to hold the propeller together. The
latter interaction helps maintain the beta turn that joins the two
beta strands either side of the Asp. The only non-DDD likely
pathogenic missense mutation identiﬁed is Leu282Pro, which
is at position 21 in the WD40 motif, adjacent to a DHSW tetrad,
where addition of a proline residue likely alters the packing of
the strands sufﬁciently to alter the hydrogen bond network in-
side the tetrad. The ﬁfth of the DDD mutations, Pro444Arg, oc-
curs at position 7 in the WD40 motif (Fig. 2B). This is not a
highly conserved position, although there are three proline resi-
dues at this position in TBLR1. Here, the fact that the amino acid
is on the domain’s top face (Fig. 4), coupledwith the dramatic na-
ture of the change, is likely to be responsible for the deleterious
effect of the mutation. The mutation places a large, charged
arginine at the protein–protein interface, and this potentially
interferes with, or disrupts, the interaction required for the
protein’s function.
To evaluate the structural impact of the missense mutations
in this domain further, the six amino acidswith likely pathogenic
missense mutations in the WD40 domain were compared with
the 29 amino acids with benign population missense variation
(Table 2). The location of these amino acids along the Z-axis of
the protein structure in PDB entry 4lg9 was analysed, i.e. through
the middle of the β-barrel, from the top to bottom face (Fig. 4A
and B), indicating that the disease-associated amino acids are
clustered in 3D space and signiﬁcantly different—closer to the
top binding face—from those associated with presumed benign
variation (P = 9 × 10−5, Fig. 4C). In addition, disease-associated
amino acids were also predicted to be signiﬁcantly different
from those associated with benign variation using PolyPhen
(15) (P = 2 × 10−8), SIFT (18) (P = 7 × 10−4), solvent-exposed surface
area (38) (P = 2 × 10−7) and residue conservation (39) (P = 8 × 10−4),
but did not differ signiﬁcantly from the tetrad or top face hotspot
residues.
Discussion
Wehave used the 3D structure of theWD40 domain encoded by
the gene TBL1XR1 to understand and characterize the differ-
ences between likely pathogenic de novo missense mutations
detected in children with severe developmental delay and pre-
sumed benign missense variation seen in population samples
and the ExAC data set. Although the variants are predicted to
result in missense changes, the true biological effect on the re-
sulting protein is unknown. As has been observed previously
across all proteins (40), the likely pathogenic mutations in
TBLR1 are generally at more buried and conserved sites when
compared with population variation. When the structure of
the WD40 domain of this protein is considered in detail,
there is notable clustering in 3D space, with likely pathogenic
mutations more likely to be near the top face of the domain.
Speciﬁcally, likely pathogenic mutations in TBLR1 all affect ei-
ther the structural rigidity of the WD40 domain β-propeller,
compromising the stability of the fold, or the physicochemical
characteristics of the top face of the β-propeller, affecting the
binding of β-catenin. The overlap of these diagnostic variants
with the previously identiﬁed symmetrically repeating DHSW
tetrads and top face hotspot residues (34) allows us to make
strong predictions about the location of other likely pathogenic
Figure 2. Conserved sequence elements of theWD40motif. (A) PROSITE sequence logo for theWD40motif, derived from amultiple sequence alignment of 6896 sequence
fragments. The one-letter amino acid codes are coloured by type (blue basic, red acidic, green and purple polar and the rest black). The height of each corresponds to its
frequency of occurrence in the alignment. (B) Structure-based alignment of the eight WD40 motifs in the crystal structure of TBLR1. The motifs were manually extracted
from the 4lg9 PDB ﬁle and then aligned using the PDBeFold Server (36). The numbers on the left show the range of residue numbers in the sequence on that line. The one-
letter amino acid codes are coloured as per the PROSITE sequence logo (A); lower-case letters correspond to residues not aligned in the 3D superposition. The numbers
along the bottom roughly correspond to the sequence positions in theWD40motif in (A). The amino acids having an orange background are those belonging to the Asp-
His-Ser/Thr-Trp tetrad. The red borders identify the ﬁve amino acids involved in the DDD missense mutations: His213Gln, Asp328Gly, Asp370Tyr, His441Arg and
Pro444Arg. The amino acids with the light grey backgrounds are the hotspot residues on the domain’s top face, as identiﬁed by WDSPdb (31), being the ones likely to
interact with β-catenin when it binds.
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genetic variations both in TBLR1 and in other instances of this
domain.
The WD40 domain is one of the top 10 most abundant
domains in eukaryotic genomes, although rarely present in
prokaryotes (22). Its primary role appears to be in making pro-
tein–protein interactions, which it can make simultaneously
with several different proteins, particularly in relation to forming
and regulating protein, DNA or RNA complexes (22,41). A number
of diseases are known to be associated with mutations in WD40
domains (23,24), including numerous developmental pheno-
types such as lissencephaly (42), short-rib thoracic dysplasia
(43) and reduced neuronal migration (44). Twenty-one proteins
containing such disease-associated mutations are listed in Sup-
plementary Material, Table S2, with their corresponding loca-
tions in the WD40 motif.
As next generation sequencing of gene panels and whole
exomes/genomes is increasingly applied in both research and
clinical settings, more and more benign and likely pathogenic
missense variants will be uncovered in known disease genes as
well as in novel disease genes. Although in silico predictions
alone should not be relied on as the sole basis to determine the
clinical signiﬁcance of missense variants in proteins, we hope
that the analysis used in this study provides useful structural
evidence for variant interpretation. Moreover, combining clinical
and population genetics with protein structural analysis offers
widely applicable in silicomethod for improving the clinical inter-
pretation of novel missense variation.
Materials and Methods
TheDDD studywas approved by the UK Research Ethics Commit-
tee (10/H0305/83, granted by the Cambridge South REC, and GEN/
284/12 granted by the Republic of Ireland REC), and appropriate
informed consent was obtained from all participants. Patients
meeting the recruitment criteria (neurodevelopmental disorder
and/or congenital anomalies, abnormal growth parameters, dys-
morphic features and unusual behavioural phenotypes) were re-
cruited to the DDD study (www.ddduk.org) by their UK NHS and
Republic of Ireland Regional Genetics Service, who also recorded
clinical information and phenotypes using the Human Pheno-
type Ontology (45) via a secure web portal within the DECIPHER
database (46). DNA samples from patients and their parents
were analysed by the Wellcome Trust Sanger Institute using
high-resolution microarray analysis (array-CGH and SNP-geno-
typing) to investigate copy number variations in the child and
by exome sequencing to investigate single nucleotide poly-
morphisms and small insertions/deletions (indels). Putative de
novo sequence variants of interest were validated in-house
using either targeted Sanger sequencing or MiSeq sequencing.
All genomic variantswere annotatedwith themost severe conse-
quence predicted by Ensembl Variant Effect Predictor (47) and
their minor allele frequencies observed in diverse population
samples. As has been described previously (20), likely diagnostic
variants were fed back to referring clinical geneticists for valid-
ation in an accredited diagnostic laboratory and discussion
with the family via patients’ record in DECIPHER, where they
can be viewed in an interactive genome browser.
In a data set of the ﬁrst 4295 family trios (child, mother and
father) with exome sequence data, we investigated genes al-
ready robustly implicated in developmental disorders with
more than three de novo mutations in DDD children, where the
consequence was predicted to result in different missense
changes. We cross-referenced this list against the Protein Data
Bank (48) to limit our analysis to genes with solved protein struc-
tures and further reﬁned the list to those where all missense
changes lay within a high-quality crystal structure from the
human-derived protein. We further excluded metalloproteins
and enzymes in which the missense variants clustered in the
catalytic site, and here we limit our discussion to just one
gene, TBL1XR1, a fairly recently identiﬁed developmental dis-
order gene (25–29), in whichmultiple likely pathogenicmissense
mutations were found in DDD that map onto a 3D protein do-
main structure.
Additional causal variants in TBL1XR1 in children with
autism/developmental delay were identiﬁed through ClinVar
(http://www.ncbi.nlm.nih.gov/clinvar/) (49) and a search of pub-
lished literature. Population variation in this genewas also inves-
tigated using the ExAC (http://exac.broadinstitute.org/; accessed
June 2015), dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), the Exome
Variant Server (NHLBI GO ESP; http://evs.gs.washington.edu/EVS/;
accessed June 2015) and the European Variant Archive (http://
www.ebi.ac.uk/eva/) (32).
Figure 3. Representation of the hydrogen-bonding network of the DHSW tetrad.
Taken from the ﬁfth WD40 motif in the 3D structure of TBLR1 (PDB entry 4lg9).
(A) Schematic representation showing the four sidechains involved: Asp370,
His348, Ser366 and Trp376. Hydrogen bonds are shown by the green dotted
lines. (B) Three-dimensional representation showing the location and
sidechains of the four tetrad residues; the rest of the domain is represented
only by backbone atoms N, Cα and C. Potential hydrogen bonds are shown by
the dashed lines. Note the importance of the highly conserved Asp370, which
can not only hydrogen-bond to the histidine, but also to the backbone of
neighbouring strands, helping hold the propeller-blade structure together.
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Supplementary Material
Supplementary Material is available at HMG online.
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